Metabolic profile and structure–activity relationship of resveratrol and its analogs in human bladder cancer cells

References

• Gambini J, Inglés M, Olaso G, et al. Properties of resveratrol: in vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans. Oxid Med Cell Longev. 2015;2015:837042. doi:10.1155/2015/65975026221416
   PubMed Web of Science ®Google Scholar
• Gliemann L. What are the chances that resveratrol will be the drug of tomorrow? Pharmacol Res. 2018;129:139–140. doi:10.1016/j.phrs.2018.02.00429425727
   PubMed Web of Science ®Google Scholar
• Wu ML, Li H, Yu LJ, et al. Short-term resveratrol exposure causes in vitro and in vivo growth inhibition and apoptosis of bladder cancer cells. PLoS One. 2018;9:e89806. doi:10.1371/journal.pone.0089806
   Google Scholar
• Bai Y, Mao QQ, Qin J, et al. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci. 2010;101:488–493. doi:10.1111/j.1349-7006.2009.01415.x20028382
   PubMed Web of Science ®Google Scholar
• Valentovic MA. Evaluation of resveratrol in cancer patients and experimental models. Adc Cancer Res. 2018;137:171–188.
   PubMed Web of Science ®Google Scholar
• Hu B, Yan Y, Tong F, et al. Lumbrokinase/paclitaxel nanoparticle complex: potential therapeutic application in bladder cancer. Int J Nanomedicine. 2018;13:3625–3640. doi:10.2147/IJN.S16643829983558
   PubMed Web of Science ®Google Scholar
• Rotches-Ribalta M, Andres-Lacueva C, Estruch R, Escribano E, Urpi-Sarda M. Pharmacokinetics of resveratrol metabolic profile in healthy humans after moderate consumption of red wine and grape extract tablets. Pharmacol Res. 2012;66:375–382. doi:10.1016/j.phrs.2012.08.00122906730
   PubMed Web of Science ®Google Scholar
• Walle T, Hsieh F, Mh D, Oatis JE Jr, Uk W. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004;32:1377–1382. doi:10.1124/dmd.104.00088515333514
   PubMed Web of Science ®Google Scholar
• Hurst S, Loi CM, Brodfuehrer J, El-Kattan A. Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opin Drug Metab Toxicol. 2007;3:469–489. doi:10.1517/17425225.3.4.46917696800
   PubMed Web of Science ®Google Scholar
• Bertacche V, Lorenzi N, Nava D, Pini E, Sinico C. Host-Guest Interaction Study of resveratrol with natural and modified cyclodextrins. J Incl Phenom Macrocycl Chem. 2006;55:279–287. doi:10.1007/s10847-006-9047-8
   Web of Science ®Google Scholar
• Das S, Lin HS, Ho PC, Ng KY. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm Res. 2008;25:2593–2600. doi:10.1007/s11095-008-9677-118629618
   PubMed Web of Science ®Google Scholar
• Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5:493–506. doi:10.1038/nrd206016732220
   PubMed Web of Science ®Google Scholar
• Kenealey JD, Subramanian L, Van Ginkel PR, et al. Resveratrol metabolites do not elicit early pro-apoptotic mechanisms in neuroblastoma cells. J Agric Food Chem. 2011;59:4979–4986. doi:10.1021/jf104901g21401048
   PubMed Web of Science ®Google Scholar
• Shu XH, Li H, Sun Z, et al. Identification of metabolic pattern and bioactive form of resveratrol in human medulloblastoma cells. Biochem Pharmacol. 2010;79:1516–1525. doi:10.1016/j.bcp.2010.01.02220105429
   PubMed Web of Science ®Google Scholar
• Yang Y, Li C, Li H, et al. Differential sensitivities of bladder cancer cell lines to resveratrol is unrelated to its metabolic profile. Oncotarget. 2017;8:40289–40304. doi:10.18632/oncotarget.1504128178690
   PubMedGoogle Scholar
• Juan ME, Maijó M, Planas JM. Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J Pharm Biomed Anal. 2010;51:391–398. doi:10.1016/j.jpba.2009.03.02619406597
   PubMed Web of Science ®Google Scholar
• Qian G, Leung SY, Lu G, Leung KS. Optimization and validation of a chromatographic method for the simultaneous quantification of six bioactive compounds in Rhizoma et Radix Polygoni Cuspidati. J Pharm Pharmacol. 2008;60:107–113. doi:10.1211/jpp.60.1.001418088511
   PubMed Web of Science ®Google Scholar
• Shu XH, Li H, Sun XX, et al. Metabolic patterns and biotransformation activities of resveratrol in human glioblastoma cells: relevance with therapeutic efficacies. PLoS One. 2011;6:e27484. doi:10.1371/journal.pone.002748422096581
   PubMed Web of Science ®Google Scholar
• Murias M, Jäger W, Handler N, et al. Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. Biochem Pharmacol. 2005;69:903–912. doi:10.1016/j.bcp.2004.12.00115748702
   PubMed Web of Science ®Google Scholar
• Nawaz W, Zhou Z, Deng S, et al. Therapeutic versatility of resveratrol derivatives. Nutrients. 2017;9:E1188. doi:10.3390/nu911118829109374
   PubMed Web of Science ®Google Scholar
• Osmond GW, Masko EM, Tyler DS, Freedland SJ, Pizzo S. In vitro and in vivo evaluation of resveratrol and 3,5-dihydroxy-4‘-acetoxy-trans-stilbene in the treatment of human prostate carcinoma and melanoma. J Surg Res. 2013;179:e141–148. doi:10.1016/j.jss.2012.02.05722482756
   PubMed Web of Science ®Google Scholar
• Liang L, Liu X, Wang Q, Cheng S, Zhang S, Zhang M. Pharmacokinetics, tissue distribution and excretion study of resveratrol and its prodrug 3,5,4‘-tri-O-acetylresveratrol in rats. Phytomedicine. 2013;20:558–563. doi:10.1016/j.phymed.2012.12.01223351959
   PubMed Web of Science ®Google Scholar
• Herath W, Khan SI, Khan IA. Microbial metabolism. Part 14. Isolation and bioactivity evaluation of microbial metabolites of resveratrol. Nat Prod Res. 2013;27:1437–1444. doi:10.1080/14786419.2012.72208922950854
   PubMed Web of Science ®Google Scholar
• Miksits M, Wlcek K, Svoboda M, et al. Antitumor activity of resveratrol and its sulfated metabolites against human breast cancer cells. Planta Med. 2009;75:1227–1230. doi:10.1055/s-0029-118553319350482
   PubMed Web of Science ®Google Scholar
• Stivala LA, Savio M, Carafoli F, et al. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem. 2001;276:22586–22594. doi:10.1074/jbc.M10184620011316812
   PubMed Web of Science ®Google Scholar
• Kim YM, Yun J, Lee CK, Lee H, Min KR, Kim Y. Oxyresveratrol and hydroxystilbene compounds. Inhibitory effect on tyrosinase and mechanism of action. J Biol Chem. 2002;277:163400–163444.
   Web of Science ®Google Scholar
• Qiu F, Komatsu K, Saito K, Kawasaki K, Yao X, Kano Y. Pharmacological properties of traditional medicines. XXII. Pharmacokinetic study of mulberroside A and its metabolites in rat. Biol Pharm Bull. 1996;19:1463–1467.8951165
   PubMed Web of Science ®Google Scholar
• Fauconneau B, Waffo-Teguo P, Huguet F, Barrier L, Decendit A, Merillon J. Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis vinifera cell cultures using in vitro tests. Life Sci. 1997;61:2103–2110.9395251
   PubMed Web of Science ®Google Scholar
• Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: what formulation solutions to bioavailability limitations?. J Control Release. 2012;158:182–193. doi:10.1016/j.jconrel.2011.09.08321978644
   PubMed Web of Science ®Google Scholar
• Smoliga JM, Blanchard O. Enhancing the delivery of resveratrol in humans: if low bioavailability is the problem, what is the solution? Molecules. 2014;19:17154–17172. doi:10.3390/molecules19111715425347459
   PubMed Web of Science ®Google Scholar